Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EBIT (2020 - 2025)

Historic EBIT for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$29.4 million.

  • Caribou Biosciences' EBIT rose 2311.31% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 388.48%. This contributed to the annual value of -$166.6 million for FY2024, which is 4356.15% down from last year.
  • Latest data reveals that Caribou Biosciences reported EBIT of -$29.4 million as of Q3 2025, which was up 2311.31% from -$47.6 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' EBIT registered a high of -$13.2 million during Q1 2021, and its lowest value of -$47.6 million during Q2 2025.
  • Moreover, its 5-year median value for EBIT was -$30.6 million (2022), whereas its average is -$30.4 million.
  • In the last 5 years, Caribou Biosciences' EBIT plummeted by 60793.79% in 2021 and then surged by 4485.81% in 2023.
  • Quarter analysis of 5 years shows Caribou Biosciences' EBIT stood at -$20.4 million in 2021, then tumbled by 49.86% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then increased by 24.37% to -$29.4 million in 2025.
  • Its EBIT stands at -$29.4 million for Q3 2025, versus -$47.6 million for Q2 2025 and -$42.9 million for Q1 2025.